{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Node-negative+Breast+Cancer",
    "query": {
      "condition": "Node-negative Breast Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1339,
    "total_pages": 134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Node-negative+Breast+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T21:20:59.686Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00958971",
      "title": "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TKI258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2009-07",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 18,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00958971"
    },
    {
      "nct_id": "NCT00938652",
      "title": "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine/carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Iniparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 519,
      "start_date": "2009-07",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2013-09-19",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00938652"
    },
    {
      "nct_id": "NCT02941926",
      "title": "Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3246,
      "start_date": "2016-11-30",
      "completion_date": "2022-11-09",
      "has_results": true,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 71,
      "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02941926"
    },
    {
      "nct_id": "NCT05216432",
      "title": "First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PIK3CA Mutation",
        "Solid Tumor, Adult",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "RLY-2608",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib 125mg",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib 400mg",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib 600mg",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060 100mg",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 930,
      "start_date": "2021-12-08",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216432"
    },
    {
      "nct_id": "NCT03554109",
      "title": "QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Aldoxorubicin HCl",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin HCL",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-09",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03554109"
    },
    {
      "nct_id": "NCT06460298",
      "title": "ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ProAgio Dose Levels (DL) 1,2,3,4",
          "type": "DRUG"
        },
        {
          "name": "ProAgio Dose Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ProDa BioTech, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2024-08-20",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06460298"
    },
    {
      "nct_id": "NCT06065748",
      "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        },
        {
          "name": "FoundationOne Liquid CDx Assay (F1LCDx)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1050,
      "start_date": "2023-12-11",
      "completion_date": "2029-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 61,
      "location_summary": "Daphne, Alabama • Auburn, California • Glendale, California + 54 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06065748"
    },
    {
      "nct_id": "NCT03107663",
      "title": "⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Positron-Emission Tomography",
        "Immunomodulation",
        "Metastatic Solid Malignancies",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "⁸⁹Zr-Df-IAB22M2C Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImaginAb, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-06-19",
      "completion_date": "2018-08-16",
      "has_results": false,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107663"
    },
    {
      "nct_id": "NCT04182516",
      "title": "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "NMS-03305293",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nerviano Medical Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2019-11-25",
      "completion_date": "2024-05-16",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04182516"
    },
    {
      "nct_id": "NCT07227233",
      "title": "Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.",
          "type": "DRUG"
        },
        {
          "name": "Treatment of physician's choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2026-03-31",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-07-21T21:20:59.686Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227233"
    }
  ]
}